Validation Data Gallery
Tested Applications
| Positive FC detected in | human PBMCs |
Recommended dilution
| Application | Dilution |
|---|---|
| This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 ul per 10^6 cells in a 100 µl suspension or 5 ul per 100 µl of whole blood. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
PE-FcA98093 targets SLAMF7/CD319 in FC applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen | Recombinant Protein 相同性解析による交差性が予測される生物種 |
| Full Name | SLAM family member 7 |
| Calculated molecular weight | 335 aa, 37 kDa |
| GenBank accession number | BC027867 |
| Gene Symbol | SLAMF7 |
| Gene ID (NCBI) | 57823 |
| Conjugate | PE Fluorescent Dye |
| Excitation/Emission maxima wavelengths | 496 nm, 565 nm / 578 nm |
| Form | Liquid |
| Purification Method | Protein A purification |
| Storage Buffer | PBS with 0.09% sodium azide and 0.5% BSA , pH 7.3 |
| Storage Conditions | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
Background Information
Signaling lymphocyte activation molecule (SLAM) family receptors is a group of type I transmembrane receptors belonging to the immunoglobulin superfamily (PMID: 37251372). The SLAM family contains nine members that contain an extracellular segment comprising two or four Ig-like domains (V-like variable and C2-like constant), a transmembrane region and a cytoplasmic tail (PMID: 29662641). They are involved in various physiological and pathological processes, including the regulation of immunological responses and the route of viral entry. SLAMF7, also known as CS1, CRACC or CD319, is expressed on NK cells, CD8+ T lymphocytes, B lymphocytes, and mature dendritic cells (PMID: 28861320). It exerts both activating and inhibitory effects depending on the expression status of SAP or EAT-2. SLAMF7 is overexpressed in multiple myeloma and makes it a target for immunotherapy (PMID: 28861320).
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for PE SLAMF7/CD319 antibody PE-FcA98093 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |